Publications by authors named "C C Nimmo"

Background: Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of Mycobacterium tuberculosis (Mtb) resistant to bedaquiline. Clinical bedaquiline resistance is most frequently conferred by off-target resistance-associated variants (RAVs) in the mmpR5 gene (Rv0678), the regulator of an efflux pump, which can also confer cross-resistance to clofazimine, another TB drug.

View Article and Find Full Text PDF

Background: Clinical bedaquiline resistance predominantly involves mutations in mmpR5 (Rv0678). However, mmpR5 resistance-associated variants (RAVs) have a variable relationship with phenotypic Mycobacterium tuberculosis resistance. We did a systematic review to assess the maximal sensitivity of sequencing bedaquiline resistance-associated genes and evaluate the association between RAVs and phenotypic resistance, using traditional and machine-based learning techniques.

View Article and Find Full Text PDF

Bedaquiline resistance is a major threat to drug-resistant tuberculosis control strategies. This analysis found a pooled prevalence of baseline bedaquiline resistance of 2.4% and a pooled prevalence of treatment-emergent bedaquiline resistance of 2.

View Article and Find Full Text PDF

Background: Clinical bedaquiline resistance predominantly involves mutations in (). However, resistance-associated variants (RAVs) have a variable relationship with phenotypic resistance. We performed a systematic review to (1) assess the maximal sensitivity of sequencing bedaquiline resistance-associated genes and (2) evaluate the association between RAVs and phenotypic resistance, using traditional and machine-based learning techniques.

View Article and Find Full Text PDF
Article Synopsis
  • New classes of antitubercular drugs, like diarylquinolines and nitroimidazoles, show promise in treating drug-resistant tuberculosis.
  • Despite their effectiveness, there are concerns about emerging resistance to these drugs.
  • A specific case is reported of a 55-year-old woman in South Africa who developed resistance to bedaquiline and delamanid while battling extensively drug-resistant tuberculosis and HIV.
View Article and Find Full Text PDF